A Novel Immunotolerizing Therapy for Autoimmune Vitiligo
一种治疗自身免疫性白癜风的新型免疫耐受疗法
基本信息
- 批准号:8713488
- 负责人:
- 金额:$ 22.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdverse effectsAdverse eventAffectAmino AcidsAnimal ModelAnimalsAppearanceAreaAutoimmune DiseasesAutoimmune ProcessBasic ScienceBloodChicagoClinicalClinical InvestigatorClinical ProtocolsClinical ResearchClinical TrialsControl GroupsDNADendritic CellsDevelopmentDiseaseDoseEnsureFamily suidaeGeneric DrugsGoalsGrowthHealthHeat-Shock Proteins 70HumanITGAM geneITGAX geneImmuneImmune ToleranceImmunologic MonitoringIncentivesInfiltrationInflammatoryInstitutionInvestigationJet InjectionsLeadLesionMeasuresMedicalMemoryModelingModificationMusNeedlesOutcome MeasurePathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhasePhase I Clinical TrialsPigmentsPlasmidsPopulationPreclinical TestingPreparationPreventionPreventiveProteinsProtocols documentationQuality of lifeRelative (related person)SafetySalineSamplingSkinSmall Business Innovation Research GrantSocial InteractionT-Cell ReceptorT-LymphocyteTechnologyTestingTherapeuticTimeToxic effectToxicologyTrainingTransgenic MiceTranslatingUnited States National Institutes of HealthUniversitiesVaccinationVariantVitiligoWorkanimal efficacybaseclinically relevantdesigninnovationinterestmanmeetingsmelanocytemelanomamouse modelnovelpre-clinicalpreclinical studyprofessorprotein expressionpublic health relevanceresponsesafety studyscale upskin colorvector
项目摘要
DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is pioneering a novel therapy to restore immune tolerance and arrest progressive depigmentation in vitiligo. At Loyola University (LUC), a variant to inducible Heat Shock Protein 70 was developed with remarkable potential for the prevention and treatment of autoimmune vitiligo. Carrying only a single amino acid modification to the protein, this variant HSP70iQ435A (designated "CM") was found to have a curative effect involving long-lasting tolerization of dendritic cells (DCs) and inhibition of T ell influx to the skin. Depigmentation was inhibited by CM DNA vaccination to a remarkable extent in both preventive and therapeutic settings using different spontaneous, T cell receptor transgenic mouse models of vitiligo. Translated to humans, the inflammatory CD11b+CD11c+ subset of DCs held responsible for precipitating and perpetuating vitiligo is found in increased abundance among circulating and skin infiltrating DC. We thus hypothesize that the CM will likewise interfere with progressive depigmentation in human vitiligo. Given the strength and innovation of the basic science investigations and the profound efficacy revealed in multiple animal models of vitiligo, and the clear path forward to clinical proof-of-concept, we now propose an SBIR Phase 1 proposal to advance the CM through demonstration of efficacy in a clinically-relevant large animal model of vitiligo. Specific Aim #1: Establish the efficacy of the M in a large vitiligo model with human-like skin. At RTX the DNA of interest will be subcloned into pUMCV3, a vector suited for human use and expression compared to the original plasmid. 150 mg of CM (>99% purity) in pUMVC3 will then be generated to support large animal efficacy studies as well as for follow-on GLP toxicology and safety pharmacology investigations. Our collaborator, Dr. Le Poole (LUC), will carry out studies in Sinclair pigs (n=6 per group). This model, developing vitiligo as well as melanoma, will serve to test CM DNA application by needle-less jet injection in a model that allows for testing in human-like skin while measuring side-effects on anti-melanoma responses. Efficacy is measured by quantifying changes in lesional area. Local and systemic adverse events will be followed, and immune monitoring performed to translate earlier findings to large animals. This includes analysis of dendritic cell and T cell profiles in blood and skin samples taken from the animals over time. Specific Aim #2: Prepare the CM for IND approval. At RTX, a clinical protocol will be prepared and studies planned to determine the NOAEL, culminating in a pre-IND meeting on preparation for IND approval for a Phase I clinical study. For follow-on GLP toxicology and safety pharmacology investigations, 150 mg of CM (>99% purity) in pUMVC3 will be generated. Clinical investigators will be trained in working with the CM and its application in a pre-clinical setting and to manage any adverse events if necessary. We expect that the CM will induce >50% reduction in vitiligo progression relative to the saline control group and that immune monitoring will determine a > 50% reduction in T cell infiltration to the skin.
描述(由申请人提供):Radikal Therapeutics(RTX)是一种新型疗法的先驱,用于恢复白癜风的免疫耐受性和阻止进行性色素脱失。在洛约拉大学(LUC),开发了一种可诱导热休克蛋白70的变体,具有预防和治疗自身免疫性白癜风的显着潜力。发现该变体HSP 70iQ435A(命名为“CM”)仅携带对蛋白质的单个氨基酸修饰,具有涉及树突状细胞(DC)的持久耐受化和T细胞流入皮肤的抑制的疗效。使用不同的自发性白癜风T细胞受体转基因小鼠模型,在预防和治疗环境中,CM DNA疫苗接种可显著抑制色素脱失。翻译到人类,炎症性CD11b+CD11c+亚群的DC负责沉淀和永久白癜风中发现增加丰度循环和皮肤浸润DC。因此,我们假设CM同样会干扰人类白癜风的进行性色素脱失。鉴于基础科学研究的实力和创新,以及在多种白癜风动物模型中揭示的深刻疗效,以及临床概念验证的明确途径,我们现在提出SBIR第1阶段建议,通过在临床相关的白癜风大型动物模型中证明疗效来推进CM。具体目标#1:在具有类人皮肤的大型白癜风模型中建立M的功效。在RTX时,将感兴趣的DNA亚克隆到pUMCV 3中,与原始质粒相比,pUMCV 3是一种适合人类使用和表达的载体。然后将在pUMVC 3中产生150 mg CM(>99%纯度),以支持大型动物疗效研究以及后续GLP毒理学和安全药理学研究。我们的合作者Le Poole博士(LUC)将在Sinclair猪中进行研究(每组n=6)。该模型开发白癜风以及黑色素瘤,将用于通过无针喷射注射在模型中测试CM DNA应用,该模型允许在人类皮肤中进行测试,同时测量对抗黑色素瘤反应的副作用。通过量化病变面积的变化来测量疗效。将跟踪局部和全身不良事件,并进行免疫监测,以将早期发现转化为大型动物。这包括分析随时间推移从动物身上采集的血液和皮肤样本中的树突状细胞和T细胞谱。具体目标#2:准备CM用于IND批准。在RTX,将制定临床方案,并计划进行研究以确定NOAEL,最终召开IND前会议,为I期临床研究的IND批准做准备。对于后续GLP毒理学和安全药理学研究,将在pUMVC 3中生成150 mg CM(>99%纯度)。临床研究者将接受CM及其在临床前环境中的应用的培训,并在必要时管理任何不良事件。我们预期,相对于盐水对照组,CM将诱导白癜风进展减少>50%,并且免疫监测将确定T细胞向皮肤的浸润减少> 50%。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The convergence theory for vitiligo: A reappraisal.
- DOI:10.1111/exd.13677
- 发表时间:2019-06
- 期刊:
- 影响因子:3.6
- 作者:Kundu RV;Mhlaba JM;Rangel SM;Le Poole IC
- 通讯作者:Le Poole IC
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW Lurie SALZMAN其他文献
ANDREW Lurie SALZMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW Lurie SALZMAN', 18)}}的其他基金
Treatment of congenital heart disease associated pulmonary hypertension
先天性心脏病相关肺动脉高压的治疗
- 批准号:
8831801 - 财政年份:2015
- 资助金额:
$ 22.5万 - 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
- 批准号:
9342949 - 财政年份:2012
- 资助金额:
$ 22.5万 - 项目类别:
Resuscitation of smoke inhalation and burn injury with a thioredoxin mimetic
用硫氧还蛋白模拟物复苏烟雾吸入和烧伤
- 批准号:
8338756 - 财政年份:2012
- 资助金额:
$ 22.5万 - 项目类别:
A Redox-active PARP Inhibitor for Lung Transplantation
用于肺移植的氧化还原活性 PARP 抑制剂
- 批准号:
8391286 - 财政年份:2012
- 资助金额:
$ 22.5万 - 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
- 批准号:
9140177 - 财政年份:2012
- 资助金额:
$ 22.5万 - 项目类别:
Bifunctional Redox Catalyst & Organic Nitrate for Limb Reperfusion
双功能氧化还原催化剂
- 批准号:
8522327 - 财政年份:2011
- 资助金额:
$ 22.5万 - 项目类别:
PARP inhibition for thoraco-abdominal aneurysm surgery
PARP 抑制在胸腹动脉瘤手术中的应用
- 批准号:
6933563 - 财政年份:2005
- 资助金额:
$ 22.5万 - 项目类别:
PARP inhibitory therapy of acute ischemic stroke
PARP抑制治疗急性缺血性脑卒中
- 批准号:
6785744 - 财政年份:2004
- 资助金额:
$ 22.5万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant